streptomycin
Trade name: kabikinase
Approved
Feb 18, 1946
Streptomycin is a water-soluble aminoglycoside derived from Streptomyces griseus. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Streptomycin is indicated for the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium). — NCATS
Clinical trial activity
15 trials · 28 clinical orgs · 5 marketing orgs
Earliest trial started Jan 1, 1991 (NCT00004689)
Timeline
1940s
1990s
- Jan 1, 1991
Earliest Phase 2 Sponsor(trial)
- Jun 30, 1998
X Gen Pharmaceuticals — Marketing Organization
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
- Bacterial 70S ribosomeINHIBITOR
Bacterial 70S ribosome inhibitor
16s RRNA
- 30S ribosomal protein S2 (rpsB) ↗
- 50S ribosomal protein L4 (rplD) ↗
- 30S ribosomal protein S15 (rpsO) ↗
- 30S ribosomal protein S16 (rpsP) ↗
- 30S ribosomal protein S17 (rpsQ) ↗
- 30S ribosomal protein S18 (rpsR) ↗
- 30S ribosomal protein S19 (rpsS) ↗
- 30S ribosomal protein S20 (rpsT) ↗
- 30S ribosomal protein S21 (rpsU) ↗
- 30S ribosomal protein S3 (rpsC) ↗
- 30S ribosomal protein S4 (rpsD) ↗
- 30S ribosomal protein S5 (rpsE) ↗
- 30S ribosomal protein S6 (rpsF) ↗
- 30S ribosomal protein S7 (rpsG) ↗
- 30S ribosomal protein S8 (rpsH) ↗
- 30S ribosomal protein S9 (rpsI) ↗
- 50S ribosomal protein L35 (rpmI) ↗
- 50S ribosomal protein L36 2 (ykgO) ↗
- 50S ribosomal protein L36 (rpmJ) ↗
- 50S ribosomal protein L3 (rplC) ↗
- 50S ribosomal protein L5 (rplE) ↗
- 50S ribosomal protein L6 (rplF) ↗
- 50S ribosomal protein L7/L12 (rplL) ↗
- 30S ribosomal protein S1 (rpsA) ↗
- 30S ribosomal protein S10 (rpsJ) ↗
- 30S ribosomal protein S11 (rpsK) ↗
- 30S ribosomal protein S12 (rpsL) ↗
- 30S ribosomal protein S13 (rpsM) ↗
- 30S ribosomal protein S14 (rpsN) ↗
- 50S ribosomal protein L10 (rplJ) ↗
- 50S ribosomal protein L11 (rplK) ↗
- 50S ribosomal protein L13 (rplM) ↗
- 50S ribosomal protein L14 (rplN) ↗
- 50S ribosomal protein L15 (rplO) ↗
- 50S ribosomal protein L16 (rplP) ↗
- 50S ribosomal protein L17 (rplQ) ↗
- 50S ribosomal protein L18 (rplR) ↗
- 50S ribosomal protein L19 (rplS) ↗
- 50S ribosomal protein L1 (rplA) ↗
- 50S ribosomal protein L20 (rplT) ↗
- 50S ribosomal protein L21 (rplU) ↗
- 50S ribosomal protein L22 (rplV) ↗
- 50S ribosomal protein L23 (rplW) ↗
- 50S ribosomal protein L24 (rplX) ↗
- 50S ribosomal protein L25 (rplY) ↗
- 50S ribosomal protein L27 (rpmA) ↗
- 50S ribosomal protein L28 (rpmB) ↗
- 50S ribosomal protein L29 (rpmC) ↗
- 50S ribosomal protein L2 (rplB) ↗
- 50S ribosomal protein L30 (rpmD) ↗
- 50S ribosomal protein L31 type B (ykgM) ↗
- 50S ribosomal protein L31 (rpmE) ↗
- 50S ribosomal protein L32 (rpmF) ↗
- 50S ribosomal protein L33 (rpmG) ↗
- 50S ribosomal protein L34 (rpmH) ↗
Approval history
- approvedFeb 18, 1946
Chemistry & pharmacology
SMILES
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O- Mol. weight
- 1457.4 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaSurotomycin ↗
- ChEMBLCHEMBL3184791 ↗
- NCATSY45QSO73OB ↗
- WikipediaStreptomycin ↗
- ChEMBLCHEMBL2375161 ↗
- ChEMBLCHEMBL372795 ↗
- ChEMBLCHEMBL453087 ↗
Also known as
- 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-o-(2-deoxy-2-methylamino-alpha-l-glucopyranosyl)-3-c-formyl-beta-l-lyxopentanofuranoside
- 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-o-(2-deoxy-2-methylamino-alpha-l-glucopyranosyl)-3-c-formyl-beta-l-lyxopentanofuranoside
- agri-strep
- agri-strep
- cb-183,315
- cb-183,315
- cb-183,315
- chemform
- chemform
- estreptomicina
- estreptomicina
- gerox
- gerox
- mannosidostreptomycin
- mannosylstreptomycin
- nsc-14083
- nsc-14083
- strepcen
- strepcen
- streptomicina
- streptomicina
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin
- streptomycin b
- streptomycin b
- streptomycini sulfas
- streptomycin sulfate
- streptomycin sulfate
- streptomycin sulfate
- streptomycin sulfate
- streptomyzin
- streptomyzin
- streptorex
- streptorex
- surotomycin
- surotomycin
- surotomycin
- surotomycin
- surotomycin
- vetstrep
- vetstrep
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04110340 | Phase 3 | Oct 1, 2019 | Hôpital Universitaire Joseph Raseta Befelatanana CHU d'Antananarivo, University of Oxford |
| NCT02354014 | Phase 2 | May 3, 2016 | Johnson and Johnson |
| NCT02365623 | Phase 2 | Feb 18, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02128308 | Phase 1 | Nov 1, 2013 | Seoul National University |
| NCT02331823 | Phase 4 | Jun 1, 2013 | Centers for Disease Control and Prevention (CDC), Government of China, Huazhong University of Science and Technology, Zhejiang University |
| NCT01659437 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2012 | Drugs for Neglected Diseases Initiative, Government of Benin, Kumasi Centre for Collaborative Research, Kwame Nkrumah University of Science and Technology, National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana, Noguchi Memorial Institute for Medical Research, University of Antwerp, University of Ghana, University of Groningen, World Alliance for Wound and Lymphoedema Care, Switzerland, World Health Organization |
| NCT01597505 | Phase 3 | May 16, 2012 | Cubist, Merck |
| NCT01598311 | Phase 3 | May 1, 2012 | Cubist, Merck |
| NCT01085591 | Phase 2 | Apr 1, 2010 | Cubist |
| NCT02835118 | Phase 1 | Jul 1, 2009 | Merck |
| NCT02835105 | Phase 1 | Jan 1, 2009 | Merck |
| NCT00128466 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2004 | Centers for Disease Control and Prevention (CDC), Food and Drug Administration, Government of Madagascar, Government of Uganda |
| NCT00000796 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00004444 | N/A | Nov 1, 1994 | Food and Drug Administration, University of Illinois at Chicago |
| NCT00004689 | Phase 2 | Jan 1, 1991 | University of Colorado, Denver |
Organizations
Research & Development (28)
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eci Pharmaceuticals Llc | For profit | MKTG | — |
| Eli Lilly | For profit | MKTG | — |
| Pfizer | For profit | MKTG | Feb 18, 1946 |
| Upjohn | For profit | NDA | Feb 18, 1946 |
| X Gen Pharmaceuticals | For profit | SYN | Jun 30, 1998 |
| X Gen Pharmaceuticals | For profit | MKTG | Jun 30, 1998 |